INKT

Mink Therapeutics Inc

INKT, USA

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilimab with ramucirumab and paclitaxel for patients with previously treated, advanced esophageal, gastric, or gastro-esophageal junction adenocarcinoma; Phase 1 trial as a monotherapy in combination with anti-PD-1 checkpoint inhibitors, pembrolizumab, and nivolumab for refractory solid tumor cancers; and Phase 1 trial for the treatment of moderate to severe viral acute respiratory distress syndrome. It is also developing MiNK-215, an IL-15 armored tumor stromal targeting the FAP-CAR-iNKT program to treat solid tumors and inflammation; and MiNK-413, an IL-15 armored CAR-iNKT program targeting B cell maturation antigen for auto-immune diseases. The company has collaborations with Autonomous Therapeutics to target and treat metastatic tumors; and ImmunoScape, Inc. to discover and develop T-cell receptor therapies against targets in solid tumors. The company was formerly known as AgenTus Therapeutics, Inc. and changed its name to MiNK Therapeutics, Inc. in June 2021. The company was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

https://minktherapeutics.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
INKT
stock
INKT

MiNK Therapeutics (NASDAQ:INKT) Stock Rating Upgraded by Wall Street Zen MarketBeat

Read more →
INKT
stock
INKT

MiNK Therapeutics, Inc. (NASDAQ:INKT) Receives Average Recommendation of “Hold” from Brokerages Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$39

Analyst Picks

Strong Buy

2

Buy

1

Hold

0

Sell

0

Strong Sell

0

Sentiment:

Neutral

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-4.08

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

21.37 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-19.30 %

Low ≤ 2%

High ≥ 10%

Investors

* Institutions hold a combined 2.30% of the total shares of Mink Therapeutics Inc

1.

Vanguard Group Inc

(0.525%)

since

2025/06/30

2.

Longbow Finance SA

(0.3685%)

since

2025/06/30

3.

Vanguard Total Stock Mkt Idx Inv

(0.3278%)

since

2025/07/31

4.

Geode Capital Management, LLC

(0.2541%)

since

2025/06/30

5.

Vanguard Institutional Extnd Mkt Idx Tr

(0.2227%)

since

2025/07/31

6.

BlackRock Inc

(0.1641%)

since

2025/06/30

7.

Fidelity Extended Market Index

(0.1214%)

since

2025/07/31

8.

Fidelity Nasdaq Composite Index

(0.0421%)

since

2025/07/31

9.

Fidelity Total Market Index

(0.0419%)

since

2025/07/31

10.

Fidelity Series Total Market Index

(0.0363%)

since

2025/07/31

11.

Spartan Extended Market Index Pool F

(0.0326%)

since

2025/07/31

12.

Wells Fargo & Co

(0.0188%)

since

2025/06/30

13.

Extended Equity Market Fund K

(0.0182%)

since

2025/06/30

14.

NT Ext Equity Mkt Idx Fd - L

(0.0162%)

since

2025/06/30

15.

Northern Trust Extended Eq Market Idx

(0.0162%)

since

2025/06/30

16.

Spartan Total Market Index Pool G

(0.0144%)

since

2025/07/31

17.

Bank of America Corp

(0.0126%)

since

2025/06/30

18.

Total Investment Management Inc

(0.0111%)

since

2025/06/30

19.

NT Ext Equity Mkt Idx Fd - NL

(0.0072%)

since

2025/06/30

20.

UBS Group AG

(0.0063%)

since

2025/06/30

21.

State St US Extended Mkt Indx NL Cl C

(0.0062%)

since

2025/08/31

22.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0056%)

since

2025/06/30

23.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.0046%)

since

2025/06/30

24.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0039%)

since

2024/12/31

25.

Covestor Ltd

(0.0029%)

since

2025/06/30

26.

BNYM Mellon SL Market Completion UC1

(0.0028%)

since

2025/06/30

27.

Advisor Group Holdings, Inc.

(0.0027%)

since

2025/06/30

28.

SSgA U.S. Total Market Index Strategy

(0.0026%)

since

2025/03/31

29.

Extended Equity Market Fund M

(0.0023%)

since

2025/06/30

30.

AVIP BlackRock Advtg Small Cp Gr Prtfl

(0.0021%)

since

2025/06/30

31.

BNP Paribas Arbitrage, SA

(0.0006%)

since

2025/06/30

32.

Morgan Stanley - Brokerage Accounts

(0.0005%)

since

2025/06/30

33.

Northwestern Mutual Wealth Management Co

(0.0004%)

since

2025/06/30

34.

Game Plan Financial Advisors, LLC

(0.0004%)

since

2025/06/30

35.

Hartland & Co

(0.0003%)

since

2025/06/30

36.

JPMorgan Chase & Co

(0.0003%)

since

2025/06/30

37.

KEY Financial, INC.

(0.0001%)

since

2025/06/30

38.

JONES FINANCIAL COMPANIES LLLP

(0%)

since

2025/06/30

39.

Hanson Mcclain Inc

(0%)

since

2025/03/31

40.

Tower Research Capital LLC

(0%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.65

EPS Estimate

-0.07

EPS Difference

-0.58

Surprise Percent

-828.5714%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(1.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(1.5)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(2.5)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.